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Abstract
Background: Treatment with anti-tuberculosis drugs may cause patients to experience serious adverse effects.
Genetic factors, such as polymorphisms of CYP genes, may increase the likelihood of a patient experiencing such
adverse drug reactions. In this systematic review and meta-analysis, we synthesised evidence for associations
between CYP genetic variants and anti-tuberculosis drug-related toxicity outcomes.
Methods: We searched MEDLINE, PubMed, EMBASE, BIOSIS and Web of Science to identify relevant studies. We
performed meta-analyses to obtain an effect estimate for each genetic variant on each outcome, and stratified all
analyses by country. We qualitatively assessed the methodological quality of the included studies.
Results: We included data from 28 distinct cohorts of patients in the review. We identified many areas of concern with
regard to the quality of included studies. Patients with homozygous mutant-type or heterozygous genotype at the
CYP2E1 RsaI polymorphism were significantly less likely to experience hepatotoxicity than patients with homozygous
wild-type genotype (odds ratio [OR] = 0.75, 95% confidence interval [CI] 0.56–1.00; p = 0.047, I2 = 58.2%). No significant
differences were observed for the CYP2E1 DraI and PstI polymorphisms. For the 96-bp deletion-insertion single-
nucleotide polymorphism (SNP) of the CYP2E1 gene, homozygous mutant-type significantly increased hepatotoxicity
risk compared with homozygous wild-type (OR = 8.20, 95% CI 1.38–48.68, I2 = 0%); no significant difference was
observed for heterozygous genotype compared with homozygous wild-type (OR = 0.77, 95% CI 0.19–3.21, I2 = 0%).
Conclusions: Generally, we identified that coverage of the association between SNPs of CYP genes and anti-
tuberculosis drug-related toxicity outcomes is incomplete. We observed significant associations between the RsaI and
96-bp deletion-insertion SNPs of the CYP2E1 gene and anti-tuberculosis drug-related hepatotoxicity. We were unable to
comment on the impact of ethnicity on the investigated associations, as information on participants’ ethnicity was
sparsely reported in the included studies.
Systematic review registration: PROSPERO registration number: CRD42017068448.
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Background
Tuberculosis (TB) is an infectious disease caused by
Mycobacterium tuberculosis bacteria and is the second
most common cause of death from an infectious disease
in adults (HIV/AIDS being the first) [1, 2]. For individ-
uals with drug-susceptible TB, the World Health Organ-
isation currently recommends combination treatment
with four first-line drugs: isoniazid, rifampicin, etham-
butol and pyrazinamide [1].
Treatment with anti-TB drugs may cause patients to
experience serious adverse effects, such as anti-TB
drug-induced hepatotoxicity (ATDH). Incidence rates of
ATDH for patients treated with the standard combin-
ation treatment have been reported to vary from 2 to
28%, depending on the treatment regimen, patient char-
acteristics (e.g. age, race and sex) and definition of
ATDH [3]. ATDH may be fatal, with reported mortality
rates of 6–12% if treatment is not stopped promptly [4].
* Correspondence: mhr@liverpool.ac.uk
1Department of Biostatistics, University of Liverpool, Liverpool L69 3GB, UK
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Richardson et al. Systematic Reviews           (2018) 7:204 
https://doi.org/10.1186/s13643-018-0861-z
ATDH and other anti-TB drug-related toxicity outcomes
may also lead to poor patient adherence, which in turn
may result in treatment failure, relapse and the emer-
gence of drug resistance [3].
Proposed genetic risk factors for ATDH include poly-
morphisms of the Cytochrome P450 (CYP) genes. CYP
genes encode the drug-metabolising CYP enzymes [5].
Therefore, CYP gene polymorphisms may affect CYP en-
zyme activity, altering the metabolic pathway of anti-TB
drugs in the liver. Consequently, hepatic adverse reactions
may occur. Toxic metabolites may also cause other ad-
verse reactions, such as maculopapular eruption (MPE),
although hepatotoxicity is the most widely studied out-
come in pharmacogenetic studies of anti-TB drugs.
Isoniazid is the anti-TB drug for which mechanisms of
the genetic contribution to ATDH have been most
widely studied. In the liver, isoniazid is first metabolised
into acetylisoniazid via N-acetyltransferase 2, followed
by hydrolysis to acetylhydrazine [6]. Acetylhydrazine is
proposed to be oxidised into hepatotoxic intermediates
by CYP2E1 [7]. Therefore, variants of the CYP2E1 gene
may be associated with isoniazid-related hepatotoxicity,
as CYP2E1 is one of the main enzymes involved in the
metabolism of isoniazid [5].
Rifampicin and pyrazinamide have also been reported
to cause hepatotoxicity [8], although the biological
mechanisms for rifampicin- and pyrazinamide-induced
hepatotoxicity remain unknown [9]. The OATP1B1*15
haplotype has been reported to be an important risk fac-
tor for rifampicin-induced liver injury [10]. No research
into genetic risk factors for pyrazinamide-induced hep-
atotoxicity has been reported [11]. Ethambutol has not
previously been reported to cause hepatotoxicity [8].
The aim of this systematic review and meta-analysis
was to evaluate the current evidence for associations be-
tween CYP genetic variants and anti-TB drug-related
toxicity. Meta-analyses investigating the association be-
tween CYP2E1 genetic variants and hepatotoxicity have
previously been published [12–16]. However, these
meta-analyses have produced some conflicting results.
For example, Wang et al. [16] identified that the CYP2E1
c1/c1 genotype significantly increases the risk of ATDH
(odds ratio [OR] = 1.32, 95% confidence interval [CI]
1.03–1.69, I2 = 55.9%%); however, Cai et al. [12] found no
significant association for this same comparison (OR= 1.28,
95% CI 0.97–1.69, I2 = 34.2%). Three other published
meta-analyses [13–15] identified a significant association
between the CYP2E1 c1/c1 genotype and increased risk of
ATDH, although the pooled ORs reported by these
meta-analyses ranged from 1.36 to 2.22. Furthermore, the
previously conducted reviews have the following limitations:
Cai et al. [12], Deng et al. [13], Sheng et al. [14] and
Wang et al. [16] all excluded studies if data required for
meta-analysis were not included in the study report.
 Cai et al. [12] excluded three studies that were non-
randomised controlled trials (RCTs), and Deng et al.
[13], Sheng et al. [14] and Sun et al. [15] all included
only case–control studies. Important evidence may
have been omitted from these reviews, as pharmaco-
genetic data may be reported in RCTs, case–control
studies or cohort studies.
 Cai et al. [12] did not assess the methodological
quality of included studies. The other previously
conducted meta-analyses used a checklist developed
by Little et al. [17] to assess study quality.
 None of the previously conducted meta-analyses
aimed to identify and synthesise data for CYP genetic
variants other than CYP2E1 genetic variants, or for
outcomes other than hepatotoxicity; such exclusions
may limit evidence-based recommendations.
We planned to overcome these limitations in our sys-
tematic review by: contacting study authors to obtain
data required for meta-analysis when it was not included
in the study report; including relevant studies regardless
of their design; and performing a rigorous quality assess-
ment of included studies. In addition, we did not exclude
studies that did not report hepatotoxicity, and we aimed
to identify and synthesise data for all CYP genetic vari-
ants. Therefore, the scope of our review is wider than
the previously conducted meta-analyses.
Methods
The current study forms part of a series of systematic re-
views and meta-analyses evaluating the influence of differ-
ent genetic variants on toxicity to anti-TB agents, the
protocol for which has been published (PROSPERO regis-
tration number: CRD42017068448) [18]. This review has
been conducted in accordance with the PRISMA state-
ment [19]; a completed copy of the PRISMA checklist is
provided in Additional file 1.
The described search strategy and study selection
methods were used to identify studies that investigated
the effect of any genetic variant (rather than specifically
CYP genetic variants) on anti-TB drug-related toxicity.
However, in this article, we focus only on studies that
reported data for the association between CYP variants
and anti-TB drug-related toxicity outcomes. Studies in-
vestigating associations between other genetic variants




Eligible study designs were cohort studies, case–control
studies and RCTs.
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Types of participants
We included studies that recruited TB patients who
were either already established on anti-TB treatment or
were commencing treatment (at least one of isoniazid,
rifampicin, pyrazinamide or ethambutol), and who had
been genotyped, in order to investigate the association
between genetic variant(s) and anti-TB drug-related tox-
icity outcomes. Specifically, we only included studies
where over 50% of included patients were TB patients
receiving anti-TB treatment, as we would then contact
study authors to obtain data for the subgroup of TB pa-
tients, as suggested in the Cochrane Handbook [20] for
studies where only a subset of the population is eligible.
Types of outcomes
Studies that measured any anti-TB drug-related toxicity
outcomes were eligible for inclusion.
Search strategy
An information specialist (Eleanor Kotas) designed the
search strategy (provided in Additional file 2). MEDLINE,
PubMed, EMBASE, BIOSIS and Web of Science were
searched for relevant studies. We hand searched the refer-
ence lists of relevant studies, and contacted experts in the
clinical area to identify further eligible studies. Only studies
published in English were included, but we did not restrict
by year of publication or by publication status.
Study selection
We imported the results of the search into Covidence
[21]. One author (MR) removed duplicates and scanned
the study abstracts to remove obviously irrelevant stud-
ies. A second author (ALJ, JK or KD) independently
screened a sample of 10% of studies.
One reviewer (MR) obtained the full text for each po-
tentially relevant study and assessed eligibility based on
the eligibility criteria. A second author (ALJ, JK or KD)
independently screened a sample of 10% of studies for
inclusion. Any disagreements between the two reviewers
at both the abstract and full-text screening stages were
resolved through discussion, or by consulting a third au-
thor if necessary.
Outcomes
The primary outcome of our review was hepatotoxicity
by any definition used by the original investigators. The
secondary outcomes were all other toxicity outcomes re-
ported in the included studies.
Data extraction
We pre-piloted a data extraction form, which was de-
signed to enable collection of data on study design, par-
ticipant characteristics, treatment regimen, genotype
groups and outcomes. One author (MR) extracted data,
following methods described in the Cochrane Handbook
[20] and The HuGENet HuGE Review Handbook [22].
A second author (ALJ, JK or KD) independently ex-
tracted all outcome data. Any disagreements between
the two reviewers were resolved through discussion, or
by consulting a third author if necessary. We contacted
study authors if outcome data required for meta-analysis
were not included in the study report.
We examined author lists, locations, dates of recruitment
and other study characteristics to identify cases of multiple
articles reporting data for overlapping or identical patient
cohorts. If we suspected that this may be the case, we con-
tacted authors to clarify whether patient cohorts were dis-
tinct. If an author clarified that multiple articles reported
outcomes for the same patient cohort, or overlapping co-
horts, or if we suspected this based on reported study char-
acteristics, we assigned a group identifier (GI) to these
articles. Assigning this GI ensured that data for each patient
cohort were only included once in any meta-analysis.
Quality assessment
One author (MR) used the criteria developed by Jorgen-
sen and Williamson [23] specifically for pharmacoge-
netic studies, to assess the methodological quality of
each included study. A second author (ALJ) independ-
ently assessed the quality of a sample of 10% of studies.
Any disagreements between the two reviewers were re-
solved through discussion. We summarised the number
of studies meeting each criterion in the text.
Data synthesis
Primary analyses
The primary analyses assessed the risk of hepatotoxicity
in individuals with homozygous mutant genotype or het-
erozygous genotype and compared it with the risk in
those with homozygous wild-type genotype for three key
single-nucleotide polymorphisms (SNPs) of the CYP2E1
gene, commonly known as the RsaI, PstI and DraI poly-
morphisms; these SNPs are the most widely studied
polymorphisms of CYP genetic variants in the context of
ATDH. Data were pooled from studies that reported
data for each genotype group separately with data from
studies that combined homozygous mutant-type and
heterozygous genotype groups.
For each SNP, sensitivity analyses were conducted to
investigate the robustness of the primary analysis by per-
forming pairwise comparisons of heterozygous versus
homozygous wild-type genotype, and homozygous mu-
tant versus homozygous wild-type genotype. For these
analyses, it was only possible to include data from stud-
ies that reported on each genotype group separately.
We produced funnel plots for each of the primary ana-
lyses (where at least ten studies were included) to inves-
tigate the possibility of publication bias.
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Secondary analyses
The secondary analyses investigated all other associations
between CYP genetic variants and anti-TB drug-related
toxicity outcomes. We performed meta-analyses for all as-
sociations that were investigated by at least two studies:
 For SNPs where all studies presented data for each
genotype group separately, we performed two
pairwise comparisons; heterozygous genotype versus
homozygous wild-type and homozygous mutant-type
versus homozygous wild-type.
 For SNPs where all studies presented data for
combined genotype groups, we performed one
comparison of the combined genotype groups.
 For SNPs where the approach varied between
studies, we pooled data for studies that reported
data for each genotype group separately with data
from studies that reported data for combined
genotype groups. We also performed pairwise
comparisons including data from studies that
reported on each genotype group separately.
For SNPs investigated by one study only, ORs compar-
ing genotype groups were calculated and summarised
with their 95% CIs in a table, together with the pooled
estimates from all meta-analyses.
All meta-analyses were performed using the metan pack-
age in Stata 14 [24]. A random-effects model was employed
because we anticipated heterogeneity between studies due to
differences in study design, quality of methods, ethnic back-
ground of participants and outcome definitions. We assessed
statistical heterogeneity by visually examining the forest plots,
and by referring to the I2 statistic. The random-effects model
used the method of DerSimonian and Laird [25], with the es-
timate of heterogeneity being taken from the Mantel–Haens-
zel model [26]. If no events occurred in one of the genotype
groups, a continuity correction of 0.5 was applied [20]. If
there were no patients in one of the genotype groups in a
comparison for a particular study, data from this study were
excluded from the meta-analysis.
According to the HuGENet HuGE Review Handbook,
meta-analyses of genetic association studies should be strati-
fied by ethnicity; results across different ethnic groups
should only be pooled if effect estimates across these groups
appear sufficiently similar [22]. Information on participants’
ethnicity was sparsely reported; however, in an attempt to
adhere with this recommendation, we performed analyses
stratified by the countries in which studies were conducted.
Results
Included and excluded studies
A PRISMA flowchart, showing selection and elimination
of studies during the literature search, is provided in
Fig. 1. We included 77 articles, and identified 53 distinct
cohorts of patients.
Thirty-three articles reported data for the association
between CYP genetic variants and anti-TB drug-related
toxicity; we identified 28 distinct cohorts of patients
from these articles. We did not include data from one
article [27], as we suspected that this article reported
data for the same group of patients included in another
paper [28]; furthermore, the data presented were unclear
and we were unable to clarify the data with the authors.
It was also excluded from our quality assessment. There-
fore, in this review, we include data from 32 articles
[28–59] (28 distinct patient cohorts). The characteristics
of studies included in this review are provided in
Additional file 3: Table S1.
Quality assessment
Choosing which genes and SNPs to genotype
Twenty articles provided justification for the choice of gene
and SNP to be investigated. For the 12 articles [31, 33, 36,
44, 46, 48, 52, 54–56, 58, 59] that did not provide justifica-
tion for each investigated gene and SNP, no articles limited
their reporting to only statistically significant associations.
Therefore, selective reporting of genes and SNPs does not
appear to be an issue of concern.
Sample size
The median sample size of included studies was 220.5
(interquartile range 155.5–332). Typically, much larger
sample sizes are required to detect genetic effects [23].
Only one article [59] reported the a priori power to de-
tect pre-specified effect sizes. Therefore, most studies
are likely to be at risk of being underpowered [23].
Study design
Twelve articles used a case–control design [29, 35, 38,
39, 41, 42, 47, 50–53, 55]; however, only 1 article [39] re-
ported that the 2 groups were genotyped in mixed
batches. Separate genotyping in case–control studies
could potentially bias the results of a study [23]. A total
of 19 articles reported prospective cohort studies [28,
30–34, 36, 37, 40, 43–46, 48, 49, 54, 56–58], and 1 art-
icle reported a retrospective cohort study [59].
Reliability of genotypes
Only 5 articles [34, 39, 50–52] mentioned genotype
quality control procedures, and therefore 27 articles may
be at risk of incorrect genotype allocation [23]. Only five
articles [37, 38, 44, 46, 49] compared genotype frequen-
cies of all investigated SNPs to previously published
genotype frequencies for the same population. Such a
simple check can be an effective method of identifying
problems with genotyping. For case–control and retro-
spective cohort studies, genotyping personnel should be
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blinded to outcome status in order to minimise the risk
of bias during the genotyping procedure [23]. However,
only 4 articles [39, 50–52] of 13 case–control/retrospect-
ive cohort studies mentioned that genotyping personnel
were blinded to outcome status.
Missing genotype data
For most articles (19/32, 59.4%), the number of participants
included in the analyses was the same as the study sample
size, so it was clear that there were no missing genotype
data. For the remaining 13 articles [34, 38, 41–43, 46, 47,
50, 51, 53, 58, 59], only 6 articles [34, 38, 47, 53, 58, 59]
summarised the extent of missing data for all genes and
SNPs analysed. No articles described checking whether
missing data were missing at random; therefore, 13 articles
are at risk of bias from non-random missing data [23].
Population stratification
Two articles [36, 46] conducted tests to detect popula-
tion stratification, but did not identify any population
stratification. One article applied a strict exclusion cri-
terion, which ensured that included patients were from a
non-diverse ethnic group [48]. All other studies are at
risk of confounding due to population stratification.
Hardy–Weinberg equilibrium
Testing for deviation from the Hardy–Weinberg equilib-
rium (HWE) can highlight genotyping errors, population
stratification and other problems [23]. Sixteen articles
[28, 34–37, 40–42, 46, 50–52, 56–59] tested for HWE
for all SNPs investigated, and a further 3 [29, 44, 53]
tested for HWE for a subset of SNPs. The remaining 13
articles did not report on HWE testing.
Mode of inheritance
Nineteen articles assumed a specific underlying mode of in-
heritance [29, 31, 32, 35, 37, 39, 42, 43, 45–47, 49, 53–59].
Three of these 19 articles detailed their reasoning behind
this assumption [32, 47, 56]; for the remaining 16 articles,
several analyses assuming different modes of inheritance
Fig. 1 PRISMA flow diagram
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may have been performed, with only the most statistically
significant being reported [23]. There is therefore a risk of
selective reporting within these 16 articles. Three articles
[41, 50, 51] conducted analyses assuming different modes
of inheritance, but only one of these articles [41] adjusted
their analyses for multiple testing; therefore, there is a risk
of an inflated type I error rate in the other two articles.
Choice and definition of outcomes
Definitions of hepatotoxicity (Additional file 4: Table S2)
varied considerably between the included studies. Of the
30 articles reporting data for this outcome, 1 article did
not define hepatotoxicity [45], 1 provided a vague defin-
ition [39] and the remaining 28 articles provided 22 dif-
ferent definitions.
Definitions of other toxicity outcomes reported are
provided in Additional file 5: Table S3. These definitions
were generally not sufficiently detailed to assess how
similar they were to each other.
Twenty-eight articles all provided justification for the
choice of outcomes. Four articles [30, 34, 53, 59] did not
provide justification for the choice of outcomes, but the
choice of outcomes was appropriate to address the main
study aim as described in the article introduction.
Therefore, there is no evidence to suggest that selective
reporting of outcomes is an issue of concern for the in-
cluded articles.
Treatment adherence
Only three articles [33, 34, 42] reported that treatment
adherence was assessed. For two of these articles, it was
not necessary to adjust for adherence in the analyses, as
patients were reported to have good treatment adher-
ence [33, 34]. The third article that assessed treatment
adherence excluded patients who did not adhere to
treatment [42]. One article [48] reported that anti-TB
drugs were administered by directly observed therapy,
short-course, so it was unnecessary to assess adherence.
Association between CYP genetic variants and anti-TB
drug-related toxicity
Data from 28 distinct cohorts across the 32 included pa-
pers were considered for the analyses of association re-
ported below.
Primary analyses: key CYP2E1 SNPs and hepatotoxicity
Forest plots displaying the results of the primary ana-
lyses are provided in Figs. 2, 3 and 4.
Patients withTT or CTgenotype at the CYP2E1 RsaI poly-
morphism were significantly less likely (p= 0.047) to experi-
ence hepatotoxicity than patients with CC genotype (OR=
0.75, 95% CI 0.56–1.00) (Fig. 2). Moderate heterogeneity was
observed in this analysis (I2 = 58.2%). The results of the sensi-
tivity analyses are provided in Additional file 6. For the
CYP2E1 RsaI polymorphism, no significant differences were
observed for either pairwise comparison (heterozygous geno-
type versus homozygous wild-type: OR= 0.80, 95% CI 0.58–
1.10, I2 = 48.4%; homozygous mutant-type versus homozy-
gous wild-type: OR= 1.03, 95% CI 0.68–1.55, I2 = 2.7%).
There was no significant difference in the risk of hepato-
toxicity between patients with AA or TA genotype at the
CYP2E1 DraI polymorphism and patients with TT geno-
type (OR = 1.23, 95% CI 0.92–1.66) (Fig. 3). Minimal het-
erogeneity was observed in this analysis (I2 = 3.1%). The
sensitivity analyses (two pairwise comparisons) also showed
no significant differences between genotype groups (hetero-
zygous genotype versus homozygous wild-type: OR = 1.28,
95% CI 0.93–1.77, I2 = 6.4%; homozygous mutant-type ver-
sus homozygous wild-type: OR = 1.34, 95% CI 0.57–3.16,
I2 = 29.4%) (Additional file 6).
There was no significant difference in the risk of hepato-
toxicity between patients with CC or GC genotype at the
CYP2E1 PstI polymorphism and patients with GG genotype
(OR = 0.78, 95% CI 0.46–1.34) (Fig. 4). Moderate heterogen-
eity was observed in this analysis (I2 = 50.3%). The sensitivity
analyses (two pairwise comparisons) also showed no signifi-
cant differences between genotype groups (heterozygous
genotype versus homozygous wild-type: OR= 1.05, 95% CI
0.66–1.65, I2 = 0%; homozygous mutant-type versus homo-
zygous wild-type: OR= 1.04, 95% CI 0.36–2.99, I2 = 0%)
(Additional file 6).
The heterogeneity observed in the analyses for the RsaI
and PstI polymorphisms may be due to the variable distribu-
tion of genotypes in different geographic areas, which we as-
sumed to be a proxy for ethnic group. Owing to the small
numbers of studies conducted in each country, it is difficult
to draw firm conclusions from the stratified analyses about
the effect of country on the investigated genetic associations.
We produced a funnel plot for each of the primary
analyses (Additional file 7). There was no evidence to
suggest that publication bias was an issue of concern.
Secondary analyses: CYP genetic variants and hepatotoxicity
The included studies reported data for 8 CYP genes and 24
SNPs (in addition to the CYP2E1 SNPs reported in the pri-
mary analyses). A summary of all data for the association be-
tween CYP genetic variants and hepatotoxicity is provided in
Table 1. There were sufficient data to perform meta-analyses
for three SNPs, and forest plots showing the results of these
meta-analyses are provided in Additional file 8. The findings
from these meta-analyses are:
 For the 96-bp deletion-insertion SNP of the CYP2E1
gene, homozygous mutant-type significantly increases
hepatotoxicity risk compared with homozygous wild-
type (OR = 8.20, 95% CI 1.38–48.68, I2 = 0%), but no
significant difference was observed for heterozygous
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genotype compared with homozygous wild-type (OR
= 0.77, 95% CI 0.19–3.21, I2 = 0%).
 For the rs4918758 SNP of the CYP2C9 gene, no
significant differences were observed for either
pairwise comparison (heterozygous genotype versus
homozygous wild-type: OR = 1.11; 95% CI 0.53–
2.31, I2 = 66.7%; homozygous mutant-type versus
homozygous wild-type: OR = 0.87, 95% CI 0.51–
1.50, I2 = 0%). The heterogeneity observed in the
heterozygous genotype versus homozygous wild-
type comparison may be due to the variable distribu-
tion of genotypes in different geographic areas.
 For the rs3745274 SNP of the CYP2B6 gene, no
significant differences were observed for either
pairwise comparison (heterozygous genotype versus
homozygous wild-type: OR = 1.49, 95% CI 0.87–2.55,
I2 = 0%; homozygous mutant-type versus homozygous
wild-type: OR = 1.51, 95% CI 0.55–4.13, I2 = 4.2%).
 Due to the small numbers of studies conducted in
each country, it is difficult to draw firm conclusions
from the stratified analyses about the effect of
country on the investigated genetic associations
Additional files 3, 4 and 5.
Secondary analyses: CYP genetic variants and other
toxicity outcomes
A summary of all data for the association between CYP
genetic variants and toxicity outcomes (other than hepato-
toxicity) is provided in Additional file 9: Table S4. It was
not possible to perform meta-analyses for any toxicity out-
comes other than hepatotoxicity as there were no compar-
isons for which more than one study provided data, so
each reported result is based on data from a single study.
Considering the impact of the CYP2E1 DraI poly-
morphism on the outcome of “adverse drug-induced
hepatotoxicity outcome” (definition unclear, this was re-
ported as a separate outcome to ATDH), no significant
association was reported for homozygous mutant-type
or heterozygous genotype versus homozygous wild-type.
For the outcome of anti-TB drug (ATD)-induced MPE,
no significant associations were observed for any of the three
Fig. 2 CYP2E1 RsaI polymorphism and anti-tuberculosis drug-induced hepatotoxicity: homozygous mutant-type (TT) or heterozygous genotype (CT) versus
homozygous wild-type (CC). The labels on this graph indicate which genotype group is favoured, i.e. the likelihood of hepatotoxicity is reduced in the
favoured genotype group. * Yamada 2009 was conducted in the latent TB population. **Asian: 72 (42%), Caucasian: 49 (29%), South Asian: 22 (13%),
Hispanic: 7 (4%), Middle Eastern: 8 (5%), First Nations: 5 (3%), Other/mixed/unknown: 7 (4%). CI confidence interval, GI group identifier, OR odds ratio
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investigated SNPs of the CYP2E1 gene (RsaI, rs2070672,
rs2070673), for two SNPs of the CYP2C9 gene (rs4918758,
rs1057910) and for one SNP of the CYP2C19 gene (-1418
C-T). For the rs9332096 SNP of the CYP2C9 gene and the
rs4986893 SNP of the CYP2C19 gene, homozygous
mutant-type or heterozygous genotype was found to signifi-
cantly decrease the likelihood of ATD-induced MPE com-
pared with homozygous wild-type (rs9332096: OR= 0.23,
95% CI 0.07–0.78; rs4986893: OR= 0.30, 95% CI 0.10–0.88).
Discussion
Meta-analyses
Where possible, we synthesised the results of the in-
cluded studies in meta-analyses. Three [13, 14, 16] of
the five previously mentioned meta-analyses performed
analyses for the RsaI and PstI polymorphisms combined,
presumably because these polymorphisms have been re-
ported to be in linkage disequilibrium [60]. The ap-
proach taken for the analysis of CYP2E1 polymorphisms
in the other two meta-analyses was unclear. However,
we identified studies reporting data for these two poly-
morphisms separately [31, 35], so we performed separate
meta-analyses for each polymorphism.
We found that patients with homozygous wild-type (TT)
or heterozygous (CT) genotype at the CYP2E1 RsaI poly-
morphism were significantly less likely to experience hepato-
toxicity than patients with CC genotype (OR = 0.75, 95% CI
0.56–1.00; p= 0.047). This result is consistent with the find-
ings of four previously conducted meta-analyses [13, 14, 16].
In general, the plausibility of the findings for a significant as-
sociation between the CYP2E1 RsaI polymorphism and
ATDH is well supported by the theory that CYP2E1 plays a
role in the pathway of the metabolism of isoniazid in the
liver [5], forming hepatotoxic intermediates [7].
We observed no significant association for the CYP2E1
DraI polymorphism and ATDH, a result which is consist-
ent with previous meta-analyses [14, 16]. We also ob-
served no significant association for the CYP2E1 PstI
polymorphism and ATDH; this result is not consistent
with the findings of previously conducted meta-analyses
[13, 14, 16]. This may be because we only included studies
that explicitly stated that results were for the PstI poly-
morphism or the RsaI/PstI polymorphisms combined (if
these alleles were in complete linkage disequilibrium),
whereas the previously conducted meta-analyses do not
mention using such an approach. The number of studies
contributing data to the analysis of the CYP2E1 PstI
Fig. 3 CYP2E1 DraI polymorphism and anti-tuberculosis drug-induced hepatotoxicity: homozygous mutant-type (AA) or heterozygous genotype
(AT) versus homozygous wild-type (TT). None of the included studies reported ethnicity so this information is not provided on the forest plot. The
labels on this graph indicate which genotype group is favoured i.e. the likelihood of hepatotoxicity is reduced in the favoured genotype group.
CI confidence interval, GI group identifier, OR odds ratio
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polymorphism was relatively small (n = 8) compared with
the number of studies contributing data to the analysis of
the CYP2E1 RsaI polymorphism (n = 23).
We identified that for the 96-bp deletion-insertion SNP
of the CYP2E1 gene, homozygous mutant-type signifi-
cantly increases hepatotoxicity risk compared with homo-
zygous wild-type (OR = 8.20, 95% CI 1.38–48.68, I2 = 0%).
To the best of our knowledge, no meta-analyses have been
previously conducted for this variant. Furthermore, we are
unaware of the publication of any other meta-analyses for
SNPs of CYP genetic variants other than the RsaI, DraI
and PstI polymorphisms, so our results add to the existing
understanding of the association between CYP genetic
variants and hepatotoxicity.
Quality assessment
We identified many areas of concern with regard to the
quality of included studies. Most studies had considerably
smaller sample sizes than would typically be required to
provide power to detect a genetic association [23]. Further-
more, readers of almost all of the included studies would
not be aware of the possibility of false-negative findings,
due to the fact that only one study reported an a priori
power calculation. We also had concerns about the possi-
bility of incorrect genotype allocation in the included stud-
ies, as 84% of studies did not describe any genotyping
quality control procedures. No studies described checking
that missing data were randomly distributed. Any deviation
from random missingness is a potential source of bias [23].
Most (91%) studies were at risk of potential bias due to
population stratification. Furthermore, 41% of the studies
did not report on testing of HWE, which can be useful for
identifying genotyping errors, population stratification and
other problems [23]. We noted that 50% of included stud-
ies may be at risk of selective reporting of analyses assum-
ing different modes of inheritance, as these studies did not
provide rationale for their selected mode of inheritance.
Most of the included studies (88%) were at risk of bias
from not adjusting for treatment adherence; the propor-
tion of variability explained by genetic factors in these
studies may be underestimated [23].
Although we identified methodological limitations of the
included studies relating to some of the quality criteria, we
did not identify any studies that were thought to be of par-
ticularly poor quality overall, so we did not consider it neces-
sary to exclude any particular study in sensitivity analyses.
Limitations
While conducting this systematic review and meta-analysis,
we found that conducting robust synthesis of the existing
evidence base is challenging, owing to variability between
studies in terms of the genetic variants investigated, how
Fig. 4 CYP2E1 PstI polymorphism and anti-TB drug-induced hepatotoxicity: homozygous mutant-type (CC) or heterozygous genotype (GC) versus
homozygous wild-type (GG). The labels on this graph indicate which genotype group is favoured i.e. the likelihood of hepatotoxicity is reduced
in the favoured genotype group. CI confidence interval, GI group identifier, OR odds ratio
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Table 1 Results of the secondary analyses: association between CYP genetic variants and hepatotoxicity
Gene Variant Comparison Country
(no. of studies)
Ethnicity OR (95% CI) # cases # controls I2 value
CYP2E1 Rs2080672 Het (AG) vs Hom
WT (AA)
China (1 study) NR 1.16 (0.72, 1.89) 86 334 N/A
Hom MT (GG) vs
Hom WT (AA)
China (1 study) NR 0.69 (0.19, 2.42) 54 228 N/A
Rs915908 Het (GA) vs Hom
WT (GG)
China (1 study) NR 0.89 (0.47, 1.69) 79 318 N/A
Hom MT (AA) vs Hom
WT (GG)
China (1 study) NR 1.09 (0.52, 2.32) 75 292 N/A
Rs8192775 Het (GA) vs Hom
WT (GG)
China (1 study) NR 1.17 (0.72, 1.90) 85 333 N/A
Hom MT (AA) vs Hom
WT (GG)
China (1 study) NR 0.76 (0.25, 2.29) 55 234 N/A
Rs2515641 Het (CT) vs Hom
WT (CC)
China (1 study) NR 1.20 (0.73, 1.99) 85 342 N/A
Hom MT (TT) vs Hom
WT (CC)
China (1 study) NR 1.31 (0.41, 4.18) 60 252 N/A
Rs2515644 Het (CA) vs Hom
WT (CC)
China (1 study) NR 1.26 (0.74, 2.15) 73 285 N/A
Hom MT (AA) vs Hom
WT (CC)
China (1 study) NR 1.04 (0.52, 2.08) 42 186 N/A
Rs2070672 Het (AG) vs Hom
WT (AA)
South Korea (1 study) NR 1.74 (0.93, 3.25) 63 149 N/A
Hom MT (GG) vs Hom
WT (AA)
South Korea (1 study) NR 0.94 (0.18, 4.85) 41 116 N/A
Rs2070673a Het (TA) vs Hom
WT (TT)
South Korea (1 study) NR 0.88 (0.48, 1.63) 59 134 N/A
Hom MT (AA) vs Hom
WT (TT)
South Korea (1 study) NR 0.75 (0.28, 1.96) 37 84 N/A
96-bp
(deletion-insertion SNP)
Het (DI) vs Hom WT
(DD)
India (1 study) NR 1.13 (0.22, 5.88) 6 98 N/A
Brazil (1 study) NR 0.25 (0.01, 4.26) 18 228 N/A
All (2 studies) 0.77 (0.19, 3.21) 24 326 0.0%
Hom MT (II) vs Hom
WT (DD)
India (1 study) NR 11.56 (1.37, 97.67) 5 55 N/A
Brazil (1 study) NR 3.72 (0.15, 94.60) 18 207 N/A
All (2 studies) 8.20 (1.38, 48.68) 23 262 0.0%
CYP2C9 Rs4918758b Het (TC) vs Hom
WT (TT)
China (1 study) NR 0.78 (0.46, 1.33) 69 285 N/A
South Korea (1 study) NR 1.66 (0.85, 3.23) 59 127 N/A
All (2 studies) 1.11 (0.53, 2.31) 128 412 66.7%
Hom MT (CC) vs Hom
WT (TT)
China (1 study) NR 0.94 (0.49, 1.80) 51 188 N/A
South Korea (1 study) NR 0.72 (0.27, 1.95) 24 80 N/A
All (2 studies) 0.87 (0.51, 1.50) 75 268 0.0%
Rs9332098 Het (GA) vs Hom
WT (GG)
China (1 study) NR 0.32 (0.07, 1.38) 88 354 N/A
Hom MT (AA) vs Hom
WT (GG)
China (1 study) NR Data excludedc
Rs9332096 Het (CT) vs Hom
WT (CC)
South Korea (1 study) NR 0.63 (0.27, 1.47) 66 156 N/A
Hom MT (TT) vs Hom
WT (CC)
South Korea (1 study) NR 0.73 (0.03, 18.24) 58 129 N/A
Rs1057910 Het (AC) vs Hom
WT (AA)
South Korea (1 study) NR 1.00 (0.34, 2.97) 64 154 N/A
Hom MT (CC) vs Hom
WT (AA)
South Korea (1 study) NR Data excludedc
Richardson et al. Systematic Reviews           (2018) 7:204 Page 10 of 15
Table 1 Results of the secondary analyses: association between CYP genetic variants and hepatotoxicity (Continued)
Gene Variant Comparison Country
(no. of studies)
Ethnicity OR (95% CI) # cases # controls I2 value
CYP2B6 rs3745274 Het (GT) vs Hom
WT (GG)
Brazil (1 study) NR 1.57 (0.71, 3.45) 30 176 N/A
Ethiopia (1 study) NR 1.42 (0.68, 2.98) 35 145 N/A
All (2 studies) 1.49 (0.87, 2.55) 65 321 0.0%
Hom MT (TT) vs
Hom WT (GG)
Brazil (1 study) NR 0.58 (0.07, 4.81) 13 103 N/A
Ethiopia (1 study) NR 1.98 (0.66, 5.87) 22 94 N/A
All (2 studies) 1.51 (0.55, 4.13) 35 197 4.2%
CYP3A4 rs12333983 Het (TA) vs Hom
WT (TT)
China (1 study) NR 1.33 (0.81, 2.18) 78 312 N/A
Hom MT (AA) vs Hom
WT (TT)
China (1 study) NR 1.33 (0.62, 2.86) 47 204 N/A
-392 A-G Het (GA) vs Hom
WT (AA)
Brazil (1 study) 42% white, 58% non-
white
0.69 (0.32, 1.47) 45 69 N/A
Hom MT (GG) vs Hom
WT (AA)
Brazil (1 study) 42% white, 58% non-
white
0.91 (0.31, 2.70) 34 45 N/A
CYP2C19 rs11568732 Het (TG) vs Hom
WT (TT)
China (1 study) NR 0.54 (0.25, 1.19) 87 350 N/A
Hom MT (GG) vs Hom
WT (TT)
China (1 study) NR 0.93 (0.10, 8.47) 80 229 N/A
rs4986894 Het (TC) vs Hom
WT (TT)
China (1 study) NR 0.95 (0.57, 1.59) 72 302 N/A
Hom MT (CC) vs Hom
WT (TT)
China (1 study) NR 1.11 (0.53, 2.32) 48 191 N/A
rs17878465 Het (CT) vs Hom
WT (CC)
South Korea (1 study) NR 0.99 (0.50, 1.94) 65 153 N/A
Hom MT (TT) vs Hom
WT (CC)
South Korea (1 study) NR 0.33 (0.02, 6.58) 49 118 N/A
rs4986893 Het (GA) vs Hom
WT (GG)
South Korea (1 study) NR 0.69 (0.31, 1.56) 66 156 N/A
Hom MT (AA) vs Hom
WT (GG)
South Korea (1 study) NR 0.74 (0.03, 18.42) 57 128 N/A
CYP3A5 rs776746 Het (AG) vs Hom
WT (AA)
Brazil (1 study) NR 1.84 (0.83, 4.05) 31 189 N/A
Hom MT (GG) vs Hom
WT (AA)
Brazil (1 study) NR Data excludedc
Number of CYP3A5*1 One copy vs zero
copies
Ethiopia (1 study) NR 1.56 (0.76, 3.20) 39 151 N/A
Two copies vs zero
copies
Ethiopia (1 study) NR 1.02 (0.21, 5.05) 24 110 N/A
CYP1A1 MspI Hom MT or Het vs
Hom WT
China (1 study) NR 1.33 (0.81, 2.19) 127 127 N/A
CYP2D6 rs1080983 Het (GA) vs Hom
WT (AA)
South Korea (1 study) NR 0.83 (0.43, 1.61) 65 152 N/A
Hom MT (GG) vs Hom
WT (AA)
South Korea (1 study) NR 0.56 (0.06, 5.11) 50 113 N/A
rs1080989 Het (GA) vs Hom
WT (AA)
South Korea (1 study) NR 0.89 (0.45, 1.74) 50 121 N/A
Hom MT (GG) vs Hom
WT (AA)
South Korea (1 study) NR 1.03 (0.47, 2.27) 36 80 N/A
CI confidence interval, Het heterozygous genotype, Hom MT homozygous mutant-type, Hom WT homozygous wild-type, N/A not applicable, NR not
reported, OR odds ratio
aThe paper (Kim 2009 [GI: KIM]) reports WT to be A and MT to be T, but data suggest that WT is T and MT is A
bOne of the studies (Kim 2009 [GI: KIM]) reports WT to be C and MT to be T, but the other study (Tang 2013b [GI: ADACS]), and the data, suggest
that WT is T and MT is C
cData excluded due to zero counts in one of the genotype groups
The italicised values are pooled results from more than one study, i.e. the results of meta-analyses
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participants are classified according to genotype, choice
and definition of outcomes, ethnicity of participants and
methodological quality. In order to address this variability,
we performed meta-analyses stratified by genetic variants,
genotype contrasts and outcomes. We also stratified further
by the country in which the study was undertaken as a
proxy variable for ethnicity, which was not widely reported.
Clearly, our approach of stratifying by country instead
of by ethnicity is not ideal, as the population of any coun-
try is often ethnically diverse. However, multiple studies
from a single country are likely to be relatively similar
with regard to the ethnicity of participants, so stratifying
by country was considered to be the most suitable alterna-
tive to stratifying by ethnicity. Consequently, we were un-
able to comment on the impact of ethnicity on the
investigated associations; this is an important limitation of
the review as the distribution of CYP alleles differs consid-
erably between different ethnic populations [61].
Due to the number of references identified by the search
strategy and the number of studies included in this review,
dual abstract screening, full text assessments and quality
assessments were only performed for a sample of the in-
cluded studies. At the abstract screening stage, if there
was any uncertainty about the relevance of an abstract,
the abstract would be included. At the full text eligibility
assessment and quality assessment stages, agreement was
good and all discrepancies were minor. All outcome data
were extracted independently by two reviewers. Therefore,
we believe that any errors during study selection, quality
assessment and data extraction are likely to be minimal
and unlikely to influence the results of our review.
An additional challenge encountered was the inconsistent
use of SNP nomenclature, which made gathering data for
meta-analyses problematic. In particular, the CYP2E1 SNPs
considered in the primary analyses were referred to in vari-
ous ways in the included studies. For example, the CYP2E1
SNP identified by rs2031920 was referred to in articles using
one or more of the following: rs2031920, “RsaI polymorph-
ism”, “1053C >T”, “-1019C >T”, “-1055C >T”. Since rs
numbers are unique to each SNP, in the first instance we
identified studies reporting data for the same SNPs by using
the rs numbers. If an article did not report the rs number,
then we searched the literature to match the reported SNP
(whatever nomenclature was used) to the rs number for that
SNP. This process was especially challenging, as we were
unable to identify a comprehensive database listing all the
various alternative names for each SNP identified by a
unique rs number.
The inconsistency in definition of hepatotoxicity across
the included articles (22 different definitions across 30
articles) introduced heterogeneity into the meta-analyses.
Jorgensen et al. [62] and Contopoulos-Ioannidis et al. [63]
also observed variability in definitions of outcomes across
pharmacogenetics studies. If outcome definitions were
more comparable between pharmacogenetic studies, the
extent of heterogeneity observed in meta-analyses would
be reduced. In the area of TB research and clinical prac-
tice, there appears to be inconsistency in how ATDH is
defined. It would be beneficial for consensus to be reached
between experts in this clinical area on the definitions of
outcomes that are commonly reported in pharmacoge-
netic studies of anti-TB drugs.
Furthermore, most studies reported that patients were
treated with a combination of anti-TB drugs, meaning that
it is very difficult to link pharmacogenomic factors to spe-
cific medications with the available data. It is possible that
some of these studies included patients with rifampicin-
or pyrazinamide-induced hepatotoxicity, for which bio-
logical mechanisms are unknown [9]. If genetic variants of
the CYP2E1 gene do not contribute to rifampicin- or
pyrazinamide-induced hepatotoxicity, the inclusion of pa-
tients with rifampicin- or pyrazinamide-induced hepato-
toxicity may have contributed to the lack of association
identified between the DraI and PstI polymorphisms and
ATDH.
Finally, our review is limited by the lack of evidence
from studies conducted in Africa. Genotype frequencies
of CYP genes vary greatly across the African continent
[64], where TB is endemic. Only two studies included in
this review were conducted in Africa; one was conducted
in Tunisia [37], and one in Ethiopia [58]. Therefore,
most of the evidence included in this review is not rep-
resentative of the global population most affected by TB.
To better understand the relationship between CYP gen-
etic variants and anti-TB drug-related toxicity outcomes
in African populations, more pharmacogenetic studies
are required from this setting.
Conclusions
Generally, we identified that coverage of the association be-
tween SNPs of CYP genes and anti-tuberculosis drug-related
toxicity outcomes is incomplete. We observed significant as-
sociations between the RsaI and 96-bp deletion-insertion
SNPs of the CYP2E1 gene and anti-tuberculosis drug-related
hepatotoxicity. We are unaware of the publication of any
other meta-analyses for SNPs of CYP genetic variants other
than the RsaI, DraI and PstI polymorphisms, so our results
add to the existing understanding of the association between
CYP genetic variants and hepatotoxicity. A stratified medi-
cine approach to TB treatment would allow the benefit-risk
ratio to be improved, therefore improving patient outcome
and reducing healthcare costs. Whilst the findings from our
meta-analyses alone lack the strength of evidence required to
support a stratified approach at this time, they suggest, par-
ticularly in the case of the CYP2E1 gene, that comprehensive
genotyping in a wider range of populations is required to es-
tablish the value of pharmacogenetics testing in the treat-
ment of TB.
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